Author + information
- Received June 6, 2018
- Revision received July 24, 2018
- Accepted July 25, 2018
- Published online March 4, 2019.
- Rebecca T. Hahn, MDa,∗ (, )
- James D. Thomas, MDb,
- Omar K. Khalique, MDa,
- João L. Cavalcante, MDc,
- Fabien Praz, MDa,d and
- William A. Zoghbi, MDe
- aNew York-Presbyterian/Columbia University Irving Medical Center, New York, New York
- bBluhm Cardiovascular Institute, Northwestern Medicine, Northwestern University, Chicago, Illinois
- cMinneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, Minnesota
- dDepartment of Cardiology, University Hospital Bern, Bern, Switzerland
- eHouston Methodist DeBakey Heart & Vascular Center, Houston, Texas
- ↵∗Address for correspondence:
Dr. Rebecca T. Hahn, Columbia University Medical Center, New York-Presbyterian Hospital, 177 Fort Washington Avenue, New York, New York 10032.
Assessing the severity of tricuspid regurgitation remains a challenging task, and although echocardiography is the test of choice, significant limitations of the current recommendations exist. Newer methods have been used in current trials of transcatheter devices and may improve our understanding of the disease process. Cardiac magnetic resonance imaging and computed tomography angiography may play significant roles as adjunctive imaging modalities. This paper reviews the imaging modalities currently used to quantify tricuspid regurgitation severity.
Dr. Hahn is the Chief Scientific Officer for the Echocardiography Core Laboratory at the Cardiovascular Research Foundation for which she receives no direct industry compensation; and has received personal fees from Abbott Vascular, Boston Scientific, Bayliss, Navigate, Philips Healthcare, and Siemens Healthineers. Dr. Thomas is a consultant for and receives honoraria from Edwards Lifesciences, Abbott, GE Healthcare, and Bay Labs; and his spouse is an employee of Bay Labs. Dr. Khalique is a member of the Speakers Bureau for Edwards Lifesciences; and is a consultant for Cephea Valves and Jenavalve. Dr. Cavalcante is a consultant for Medtronic and Mitralign; and has received research support from Medtronic, Siemens and Circle CVI. Dr. Praz is a consultant for Edwards Lifesciences. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received June 6, 2018.
- Revision received July 24, 2018.
- Accepted July 25, 2018.
- 2019 American College of Cardiology Foundation